Literature DB >> 15246213

Prophylactic phenytoin does not improve cerebral edema or survival in acute liver failure--a controlled clinical trial.

Vikram Bhatia1, Yogesh Batra, Subrat Kumar Acharya.   

Abstract

BACKGROUND/AIMS: Seizure activity in patients with acute liver failure (ALF) may increase cerebral oxygen requirements and worsen cerebral edema. Recently, prophylactic phenytoin has been recommended to suppress sub-clinical seizure activity evident on electroencephalographic monitoring. To determine the clinical utility of prophylactic phenytoin therapy in patients with ALF.
METHODS: Forty two patients with ALF were randomized. Twenty two patients were given prophylactic phenytoin and 22 patients acted as controls. The baseline clinical and biochemical features were similar in the two groups and patients with > or =2 poor prognostic variables were equally represented.
RESULTS: Sixteen patients in the phenytoin group, and 15 in the control group developed cerebral edema (P=0.38). Mechanical ventilation was required in 10 and 12 patients in the phenytoin and control groups, respectively, (P=0.77). Seizures occurred in 5 (22.7%) control patients and 5 (25%) phenytoin treated patients (P=0.86). Fourteen (70%) patients randomized to phenytoin and 15 (68.2%) control patients died (P=0.89).
CONCLUSIONS: Seizure was common in patients with ALF. Prophylactic use of phenytoin did not prevent cerebral edema, seizures or need for mechanical ventilation, and did not improve survival.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15246213     DOI: 10.1016/j.jhep.2004.03.017

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  22 in total

Review 1.  Intracranial hemorrhage.

Authors:  Andrew M Naidech
Journal:  Am J Respir Crit Care Med       Date:  2011-11-01       Impact factor: 21.405

Review 2.  Brain edema in acute liver failure: can it be prevented? Can it be treated?

Authors:  Andres T Blei
Journal:  J Hepatol       Date:  2007-02-05       Impact factor: 25.083

Review 3.  Therapy of intracranial hypertension in patients with fulminant hepatic failure.

Authors:  Murugan Raghavan; Paul E Marik
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

Review 4.  Management in acute liver failure.

Authors:  Subrat K Acharya
Journal:  J Clin Exp Hepatol       Date:  2014-12-03

Review 5.  Neurological management of fulminant hepatic failure.

Authors:  Jennifer A Frontera; Thomas Kalb
Journal:  Neurocrit Care       Date:  2011-04       Impact factor: 3.210

6.  A 7-day profile of oxidative stress and antioxidant status in patients with acute liver failure.

Authors:  Vikram Bhatia; Payal Bhardwaj; Jessina Elikkottil; Jyoti Batra; Anoop Saraya
Journal:  Hepatol Int       Date:  2008-09-16       Impact factor: 6.047

Review 7.  Acute Fatty Liver of Pregnancy: Pathophysiology, Anesthetic Implications, and Obstetrical Management.

Authors:  Emily E Naoum; Lisa R Leffert; Hovig V Chitilian; Kathryn J Gray; Brian T Bateman
Journal:  Anesthesiology       Date:  2019-03       Impact factor: 7.892

8.  Management of hepatic encephalopathy.

Authors:  Jennifer A Frontera
Journal:  Curr Treat Options Neurol       Date:  2014-06       Impact factor: 3.598

Review 9.  Management of acute liver failure.

Authors:  R Todd Stravitz; David J Kramer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-08-04       Impact factor: 46.802

10.  Evaluation of mannitol effect in patients with acute hepatic failure and acute-on-chronic liver failure using conventional MRI, diffusion tensor imaging and in-vivo proton MR spectroscopy.

Authors:  Vivek-A Saraswat; Sona Saksena; Kavindra Nath; Pranav Mandal; Jitesh Singh; M-Albert Thomas; Ramkishore-S Rathore; Rakesh-K Gupta
Journal:  World J Gastroenterol       Date:  2008-07-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.